Hazlett Burt & Watson Inc. buy 3,116 Johnson & Johnson (NYSE:JNJ) shares

Hazlett Burt & Watson Inc. boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 21.3% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,742 shares of the company’s stock after acquiring an additional 3,116 shares during the quarter. Johnson & Johnson comprises 1.3% of Hazlett Burt & Watson Inc.’s portfolio, making it its 11th largest holding. Holdings held by Hazlett Burt & Watson Inc. in Johnson & Johnson were worth $2,590,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Norges Bank bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $4,071,642,000. Wellington Management Group LLP boosted its holdings in Johnson & Johnson by 16.4% in the 4th quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company’s stock valued at $3,764,852,000 after buying an additional 3,391,657 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Johnson & Johnson by 16.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 21,834,359 shares of the company’s stock worth $3,453,978,000 after buying an additional 3,139,499 shares during the period. Ninety One UK Ltd boosted its holdings in shares of Johnson & Johnson by 59.0% during the second quarter. Ninety One UK Ltd now owns 6,708,943 shares of the company’s stock worth $980,579,000 after purchasing an additional 2,489,925 shares in the last quarter. Finally, Swedbank AB bought a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $331,178,000. 69.55% of shares are held by institutional investors.

The Wall Street analyst weighs in

Several analysts have weighed in on the stock. Sanford C. Bernstein lifted their price objective on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. TD Cowen cut their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Morgan Stanley boosted their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. StockNews.com lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday, September 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Monday. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $173.21, according to MarketBeat.

Read our latest research report on JNJ

Johnson & Johnson stock performance

NYSE JNJ opened at $164.64 on Friday. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The stock has a market cap of $396.24 billion, a PE ratio of 10.26, a PEG ratio of 2.71 and a beta of 0.53. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85, and a current ratio of 1.07. The company’s fifty day moving average price is $159.17 and its two hundred day moving average price is $154.00.

Johnson & Johnson (NYSE:JNJ – Get Your Free Report ) last issued its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. In the same quarter last year, the firm earned $2.80 EPS. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. On average, equities analysts expect that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were given a $1.24 dividend. This represents an annualized dividend of $4.96 and a yield of 3.01%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Indoor activity

In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC’s website. Insiders own 0.16% of the company’s shares.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.

Featured stories

Want to see what other hedge funds JNJ owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJ – Free Report).

Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.